Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

REDWOOD CITY, Calif., February 27, 2025–Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024.Read More